SMTL ID : 4b6l.1

Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x 9ZP: 4-[[(4R)-5-cyclopentyl-4-ethyl-3a,4-dihydro-3H-[1,2,4]triazolo[4,3-f]pteridin-7-yl]amino]-N-cyclopropyl-3-methoxy-benzamide(Non-covalent)

9ZP.1: 16 residues within 4Å: Chain A: R.15, L.16, L.17, G.18, C.25, A.38, K.40, V.72, L.88, E.89, L.90, C.91, S.92, K.94, H.98, F.141 19 PLIP interactions: 19 interactions with chain A Hydrophobic interactions: A:L.17, A:L.17, A:L.17, A:A.38, A:K.40, A:K.94, A:K.94, A:F.141 Hydrogen bonds: A:R.15, A:L.17, A:C.91, A:C.91 Water bridges: A:K.94, A:K.94, A:D.152, A:D.152, A:D.152, A:D.152 pi-Stacking: A:F.141

1 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 5 residues within 4Å: Chain A: H.126, P.188, V.192, S.253, I.254 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:I.254 Water bridges: A:D.255 Salt bridges: A:H.126

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Brown, K. et al., Discovery of Oral Polo-Like Kinase (Plk) Inhibitors with Enhanced Selectivity Profile Using Residue Targeted Drug Design. To be Published

Release Date

2013-08-21

Peptides

SERINE/THREONINE-PROTEIN KINASE PLK3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

SERINE/THREONINE-PROTEIN KINASE PLK3